As women navigate the hormonal shifts of perimenopause, many explore various supplements to support their well-being. Inositol, particularly myo-inositol and D-chiro-inositol, is a compound that has gained attention for its potential roles in various bodily functions. While generally considered well-tolerated, understanding potential inositol side effects is important for informed use.
This article aims to provide an evidence-based overview of the common side effects associated with inositol supplementation, particularly relevant for women in perimenopause. We’ll explore what the research indicates regarding their frequency and severity, and offer practical strategies for managing them, always emphasizing the importance of individual consultation with a healthcare provider.
What is Inositol and Why is it Considered?
Inositol refers to a group of nine naturally occurring stereoisomers, with myo-inositol and D-chiro-inositol being the most studied forms in human health. These compounds are involved in various cellular processes, including cell signaling and insulin pathways. While research on inositol often focuses on conditions like Polycystic Ovary Syndrome (PCOS) [1][2], perimenopausal women may consider it for other reasons related to metabolic or hormonal balance, though it is worth being clear at the outset that the controlled-trial evidence on inositol comes overwhelmingly from women with PCOS and from pregnancy. Trials in perimenopausal women specifically are scarce, so most of what is known about how inositol is tolerated, including the doses involved, is carried over from those groups.
The mechanisms by which inositol may exert its effects are complex, often revolving around its role as a secondary messenger in various biological pathways. For instance, inositol has been studied for its potential to support metabolic profiles in women with PCOS [3].
Common Inositol Side Effects: Gastrointestinal Discomfort
The side effects reported with inositol supplementation are generally mild and primarily involve the gastrointestinal system. The most directly relevant figure comes from a review of inositol’s clinical safety data, which found that nausea, flatulence and diarrhea appeared only at the highest dose it assessed, 12 grams per day, and that the severity of those effects did not increase as the dose rose [4]. That is a more useful thing to know than a bare list of symptoms: it puts a number on where the complaints showed up.
Most of the published safety data compares inositol against metformin rather than against placebo, and in that comparison inositol is the better-tolerated option. The systematic review and meta-analysis that informed the 2023 international PCOS guidelines concluded that myo-inositol likely causes fewer gastrointestinal adverse events than metformin, and that these are typically mild and self-limited [1]. A separate meta-analysis of trials comparing the two head to head found a roughly five-fold higher risk of adverse events on metformin than on myo-inositol (risk ratio 5.17, 95% confidence interval 2.91 to 9.17) [5]. A third review of randomized trials concluded simply that inositol is an effective and safe treatment in PCOS [2].
It is worth being precise about what that comparison establishes. It shows that inositol is tolerated better than a drug well known for gastrointestinal effects, which is not the same as establishing how often inositol causes them on its own. Where such effects have been recorded, they were described as mild and self-limited [1], and severity did not worsen at higher doses [4]. None of these trials, however, were designed to measure how many people stop taking inositol because of them, so read “mild” as a description of what the studies found rather than as a prediction about any individual.
Are There Other Noted Side Effects?
Beyond gastrointestinal effects, no other category of adverse event has emerged consistently across the published reviews. The safety review covering both non-clinical and clinical data identified gastrointestinal complaints at the top dose as its only notable finding [4], and the PCOS reviews report no other significant safety signal [1][2]. That is genuinely reassuring, but it is worth knowing that the absence of a reported signal is weaker evidence than a study built to look for one, and none of these reviews set out to detect rare harms.
It is worth being explicit about who was actually studied. The safety record comes from women with PCOS and from pregnant women taking myo-inositol to prevent gestational diabetes [6]. The Cochrane review of that pregnancy evidence is unusually candid about its own limits: six of its seven trials were run in Italy and one in Ireland, the dose and timing varied between them, and it explicitly calls for future trials to report potential harms because the existing ones were not powered to detect uncommon ones [6]. Those are the people the safety record describes.
The safety profile of inositol is considered favorable in the context of its studied applications. For instance, in comparative analyses with other compounds like metformin, inositol has been noted for its safety and tolerability [7].
Managing Inositol Side Effects in Perimenopause
For perimenopausal women considering or currently taking inositol and experiencing mild gastrointestinal side effects, several strategies may help manage discomfort. Starting with a lower dose and gradually increasing it can allow the body to adapt, potentially reducing the likelihood of symptoms. Note that dose appears to affect whether these complaints show up at all rather than how bad they get [4], so titrating is about avoiding them, not about softening them. Taking inositol with food may also help to buffer its effects on the digestive system.
Dividing the daily dose into smaller, more frequent administrations throughout the day, rather than taking one large dose, could also be beneficial. If symptoms persist or are bothersome, reducing the dose or temporarily pausing supplementation before reintroducing it at a lower amount might be considered. Open communication with a healthcare provider is always recommended to discuss any persistent symptoms or concerns.
It is important to remember that while the available evidence suggests inositol is generally safe with mild, manageable side effects [1][2], individual experiences can differ. Monitoring your body’s response and making adjustments under professional guidance is key.
Important Considerations for Perimenopausal Women
While the published trials largely support inositol’s safety profile, perimenopause is a unique physiological stage characterized by fluctuating hormones and potential changes in overall health. Therefore, women in this phase should approach any new supplement with caution and informed discussion with their healthcare provider.
No trial in this reference list measured inositol’s side effects in perimenopausal women. The safety data described above comes from women with PCOS and from pregnancy [1][2][6]. Carrying it across to perimenopause is a reasonable working assumption, because gastrointestinal complaints from several grams of a sugar alcohol are more plausibly a property of the dose than of a reproductive stage. It remains an assumption rather than a finding, and none of the cited papers make it.
It is always advisable to discuss any existing health conditions, current medications, and other supplements with a healthcare provider before starting inositol. This ensures that inositol is appropriate for your individual health profile and helps to identify any potential interactions or contraindications, which the trials summarized here were never designed to catalogue.
References
- Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines. The Journal of clinical endocrinology and metabolism, 2024. A correction was published for this article in 2024
- Inositol is an effective and safe treatment in polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reproductive biology and endocrinology : RB&E, 2023
- Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reproductive health, 2021
- Inositol safety: clinical evidences. European review for medical and pharmacological sciences, 2011
- Short-term effects of metformin and myo-inositol in women with polycystic ovarian syndrome (PCOS): a meta-analysis of randomized clinical trials. Gynecological endocrinology, 2019
- Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. The Cochrane database of systematic reviews, 2023
- Metformin and Myo-Inositol: A Comparative Analysis. Gynecologic and obstetric investigation, 2025
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
